Medpace Holdings, Inc. (MEDP)

From the record

Medpace Holdings, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Medpace Holdings, Inc.'s 10 filed years say what it did: revenue went from $422 million in fiscal 2016 to $2.5 billion in fiscal 2025, up 22% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Medpace Holdings, Inc.'s diluted share count shrank about 4.3% a year, and dividends and buybacks returned about 70% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 56 sales (1 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-02 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Medpace Holdings, Inc. earned about 98 cents of profit for every dollar of shareholders' money. Leverage: it owed about 77 cents per dollar of assets, and net share issuance: its share count shrank 7.8% over the year (the filed statements).

From the record

Medpace Holdings, Inc.'s standing among 12 graded names in its industry family: revenue of $2.5 billion in fiscal 2025 ranks in the top 37% by size; a net margin of 17.8% ranks in the top 12%; revenue growth of 20.1% a year over the last 3 filed years ranks in the top 12% (its annual reports).

From the record

Medpace Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Troendle, August J. (President & CEO, as filed), filing under that title since 2016-08-10, 10.3 years (top 7% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 9.3 years (top 6%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 33%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Medpace Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $497 million against no long-term debt tagged leaves 25.2% of its assets as net cash, top 29% of its family; cash from operations less capital spending is 26.9% of revenue (top 12%) (its annual report).

From the record

Medpace Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 20.1% a year over the last three filed years against 22% over all 10, slowing (top 37% of its family); the newest year grew 20% (top 21%); capital spending grew -5.3% a year (top 37%) (its annual reports). Medpace Holdings, Inc. reported 6 product lines in fiscal 2025: Oncology at $748 million (30%), Metabolic at $745 million (29%), Other at $409 million (16%), and 3 more; 4 of 6 grew against the year before (its annual report).

From the record

Medpace Holdings, Inc.'s newest year against its own record: revenue of $2.5 billion in fiscal 2025 came in 0.2% below the $2.5 billion its prior three years' pace pointed to (top 41% of its family); net income of $451 million against a prior three-year average of $311 million (top 23%); a net margin of 17.8% against 17% before (top 32%) (its annual reports).